WilmerHale Advises Underwriters in Follow-on Public Offering of Viridian Therapeutics

WilmerHale Advises Underwriters in Follow-on Public Offering of Viridian Therapeutics

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale represented the underwriters in the follow-on public offering of 7,142,858 shares of common stock of Viridian Therapeutics, Inc., a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases. The shares of common stock were issued at a public offering price of $21.00 per share. The gross proceeds to Viridian were $150 million, before deducting underwriting discounts, commissions and offering expenses. The offering priced on January 17, 2024 and closed on January 22, 2024.

The WilmerHale team representing the underwriters consisted of Lisa Firenze, Molly Fox, Katharine Patterson and Milan Kumar, with assistance from Bruce Manheim and Barish Ozdamar.

 

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel